Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083966 | 1.00 | HRH3 (0.72) | HRH3MAOBRAB9ANPC1MAPK1 | |
| SCHEMBL491666 | 1.00 | HRH3 (0.72) | HRH3MAOBRAB9ANPC1MAPK1 | |
| SCHEMBL491668 | 1.00 | HRH3 (0.72) | HRH3MAOBRAB9ANPC1MAPK1 | |
| SCHEMBL4094371 | 0.89 | HRH3 (0.62) | HRH3MAOBHRH1KDM4ESMN1; SMN2 | |
| SCHEMBL4093906 | 0.89 | HRH3 (0.62) | HRH3MAOBRAB9ANPC1HRH1 | |
| SCHEMBL4597205 | 0.89 | HRH3 (0.62) | HRH3MAOBRAB9ANPC1HRH1 | |
| SCHEMBL4093895 | 0.89 | HRH3 (0.62) | HRH3MAOBRAB9ANPC1HRH1 | |
| SCHEMBL4094374 | 0.89 | HRH3 (0.62) | HRH3MAOBHRH1KDM4ESMN1; SMN2 | |
| SCHEMBL4094378 | 0.89 | HRH3 (0.62) | HRH3MAOBHRH1KDM4ESMN1; SMN2 | |
| SCHEMBL4093901 | 0.89 | HRH3 (0.62) | HRH3MAOBRAB9ANPC1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106041-B2 | Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2012-01-31 | — | — | US | disclosed |
| EP-1641461-B1 | COMBINATION PRODUCT COMPRISING AN ANTAGONIST OR INVERSE AGONIST OF HISTAMINE RECEPTOR H<SB>3</SB> AND AN ANTIPSYCHOTIC OR ANTIDEPRESSANT AGENT, AND USE THEREOF FOR THE PREPARATION OF A MEDICAMENT THAT PREVENTS THE ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS | BIOPROJET SOC CIV (FR) | 2010-09-29 | — | — | EP | disclosed |
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | HRH3, HRH4, HRH2 | HRH3 1/4885MAOB 580/4885RAB9A 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.